2017
NSI‐189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats
Abstract: Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI‐189, an orally active, new molecular entity (mol. wt. 366) with enhanced neurogenic activity, and indicated as an anti‐depressant drug in a clinical trial (Fava et al., 2015, Molecular Psychiatry, DOI: 10.1038/mp.2015.178) and being tested in a Phase 2 efficacy trial (ClinicalTrials.gov, 2016, ClinicalTrials.gov Identifier: NCT02695472) for treatment of major depression. Oral…
Search citation statements
Paper Sections
Select...
18
2
2
1
Citation Types
3
13
0
0
Year Published
2017
2025
Publication Types
Select...
22
Relationship
1
21
Authors
Journals
Cited by 22 publications
(16 citation statements)
References 47 publications
3
13
0
0
“…Our finding that NSI-189 enhanced neurite outgrowth in adult sensory neuron cultures extends the known cellular actions of this molecule to promoting regenerative growth of PNS axons. Stimulation of neurite growth is consistent with a prior report that NSI-189 increased hippocampal MAP2 expression (16), as MAP2 stabilizes microtubules and assists neurite elongation. Moreover, enhanced neurite extension by adult sensory diabetic neuron cultures was accompanied by stimulation of mitochondrial maximal respiratory capacity.…”
Section: Discussionsupporting
confidence: 92%
“…Our finding that NSI-189 enhanced neurite outgrowth in adult sensory neuron cultures extends the known cellular actions of this molecule to promoting regenerative growth of PNS axons. Stimulation of neurite growth is consistent with a prior report that NSI-189 increased hippocampal MAP2 expression (16), as MAP2 stabilizes microtubules and assists neurite elongation. Moreover, enhanced neurite extension by adult sensory diabetic neuron cultures was accompanied by stimulation of mitochondrial maximal respiratory capacity.…”
Section: Discussionsupporting
confidence: 92%
“…This is consistent with reports that long-term potentiation is impaired in diabetic rodents and that NSI-189 enhances long-term potentiation in mouse hippocampal slice preparations (18). Bioactivity of NSI-189 requires protein synthesis (18), and it increases expression of the neurotrophic factor BDNF by hippocampal cells in culture (16). Interestingly, BDNF is reduced in the hippocampus of db/db mice.…”
Section: Discussionsupporting
confidence: 91%
“…We next compared in mice the efficacy of P7C3-A20 to that of NSI-189, an experimental proneurogenic drug that acts by unknown mechanisms to enhance hippocampal neurogenesis. To date, NSI-189 has shown protective efficacy in a rat model of stroke 60 , as well as a promising effect in a phase1B randomized double-blinded placebo-controlled multiple dose-escalation study in adult patients with major depressive disorder 61 . We first compared P7C3-A20 to NSI-189 for the ability to increase the net magnitude of hippocampal neurogenesis in a standard 5 day in vivo assay of BrdU-labeled cells in the dentate gyrus 17 .…”
Section: Resultsmentioning
confidence: 99%
